An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
ACTIVE_NOT_RECRUITING
Status
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna